Scinai Immunotherapeutics (SCNI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significant bank loan into equity to secure its Nasdaq listing compliance, expected by August 23, 2024. The company also reported confidence in their contract development and manufacturing organization (CDMO) services, with projected sales growth following positive market engagement and development milestones in its pipeline, including promising results for a psoriasis treatment and strategic partnership pursuits for its NanoAb therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
